Viapaed Study In Children And Adolescents With Asthma

GlaxoSmithKline285 enrolled

Overview

Asthmatic children who remain symptomatic on inhaled corticosteroids (ICS) require an adjustment of their asthma therapy. Current guidelines suggest that the treatment options are either an increased dose of inhaled corticosteroid or the addition of other therapy such as a long-acting beta-agonist (LABA). In the pediatric age range, major concerns with respect to high dose ICS therapy are growth retardation and the suppression of the hypothalamic-pituitary-adrenocortical (HPA) axis. Previous studies in adults have shown that a combination product that included a LABA as well as the ICS allowed to reduce the steroid dose and was still at least as effective in achieving asthma control as treatment with a higher dose of ICS. These treatment options shall be compared in the present study. Children who remain symptomatic while inhaling 100 µg fluticasone (FP) twice daily shall be randomized to receive the salmeterol/ fluticasone combination product, Viani (SERETIDE) 50/100 µg, or fluticasone 200 µg as a comparator drug, inhaled twice daily via the DISKUS for a period of eight weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Enrollment

285

Conditions

Asthma

Interventions

Eligibility

Sex: ALLMin age: 4 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children aged 4 to 16 years with an established history of perennial asthma. * Subjects who are treated with an inhaled corticosteroid according to BDP (budesonide) 200-400 µg/day or equivalent during the last 4 weeks before run-in. * 15 minutes after inhaling 200µg of salbutamol, reversible increase in FEV1 of at least 12% of the pre-dose value. * Willingness to substitute previous controller medication on the twice daily inhalation of fluticasone 100µg bid via DISKUS®. * Subjects/guardians who have given written informed consent to participate in the study. * Subjects /guardians who are able to understand and complete a diary record card (DRC). * Subjects who are able to use a Mini-Wright Peak Flow meter. * Sexually active female adolescents must use adequate contraception. * Willingness to refrain from any other controller medication (including anti-leukotrienes) or from regular use of short-acting beta agonists or anticholinergics during the treatment period.

Locations (98)

GSK Investigational Site

Bad Krozingen, Baden-Wurttemberg, Germany

GSK Investigational Site

Bönnigheim, Baden-Wurttemberg, Germany

GSK Investigational Site

Ettenheim, Baden-Wurttemberg, Germany

GSK Investigational Site

Heidelberg, Baden-Wurttemberg, Germany

GSK Investigational Site

Kehl, Baden-Wurttemberg, Germany

Outcomes

Primary Outcomes

Change from Baseline in mean morning peak expiratory flow (PEF)

The PEF is a person's maximum speed of expiration. PEF will be measured using a mini wright peak flow meter and will be documented daily at morning in the diary of subjects

Time frame: Baseline up to Week 8

Secondary Outcomes

Daily Asthma symptom score

Asthma symptoms will be recorded separately for night and day using 2 symptom scores. Symptoms included will be coughing, wheezing, shortness of breath, feeling of tightness in the chest and nocturnal waking due to 1 or more of these symptoms. Score will range from 0-4 where 0 = no complaints and 4= person could not sleep due to asthma symptoms.

Time frame: Up to Week 8

Number of calendar days without asthma symptoms

Number of calendar days without asthma symptoms will be defined as the sum of all days for which the patient documented an asthma symptom score of 0 (no complaints) for the day and the previous night.

Time frame: Up to Week 8

Number of necessary administrations of salbutamol

The number of necessary administrations of salbutamol will be documented daily by subjects in the diary.

Time frame: Up to Week 8

Number of weeks with good asthma control

One week of well controlled asthma will be defined by fulfilling the following criteria: at least 2 of the following criteria (type A): symptoms with a symptom score \>1 on at most 2 days, use of rescue medication maximally 4 x per week, morning PEF daily \>=80% of the predicted normal value and all the following criteria (type B): no nocturnal waking due to bronchial asthma, no exacerbations, no out-patient or hospitalized emergency treatment due to asthma, no adverse events due to administration of the study medication which would have necessitated a change of treatment, no intolerance or refusal of study medication

Time frame: Up to Week 8

Change in forced vital capacity (FVC) in % of reference value

FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deep breath.

Time frame: Up to Week 8

Change in forced expiratory volume in 1 second (FEV1) in % of reference value

FEV1 is the volume of air exhaled under forced conditions in 1 second.

Time frame: Up to Week 8

Change in peak expiratory flow rate (PEFR) in % of reference value

PEFR is a person's maximum speed of expiration.

Time frame: Up to Week 8

Change in mean morning peak flow in % of reference value

The PEF is a person's maximum speed of expiration. PEF will be measured using a mini wright peak flow meter

Time frame: Up to Week 8

Percentage of subjects with a peak flow variability of 20%

Morning versus evening peak flow will be calculated and compared.

Time frame: Up to Week 8

Number of subject withdrawals due to asthma exacerbations

Asthma exacerbations are acute or sub acute episodes, which are characterized by a progressive increase in one or more typical asthma symptoms.

Time frame: Up to Week 8

Number of subjects with adverse events (AEs)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame: Up to Week 8